Immune checkpoint inhibitors have demonstrated their efficacy in the treatment of a broad range of tumor types, establishing the drug class as an effective treatment option against cancer. China…
The hepatocellular carcinoma market in China is poised to experience substantial market growth over the 2021-2031 period. In China, even though systemic targeted drugs for hepatocellular carcinoma…
China’s psoriasis market has grown significantly over the last few years owing to the growing use of biologics to treat the disease. We expect the market to expand further over the 2021-2031…
Squamous cell carcinoma of the head and neck (SCCHN)—one of the most commonly diagnosed cancers in China—has a dynamic drug development pipeline, including targeted and biomarker-driven…
China has the greatest burden of hepatitis C virus (HCV) in the world. Chronically infected HCV patients are at a high risk of developing cirrhosis, liver cancer, and early death if left untreated…
Breast cancer is the most commonly diagnosed cancer in women in China. The disease has been managed primarily through chemotherapy in China, but several novel, premium-priced targeted therapies—…
China has the highest incidence of gastroesophageal cancer globally, and therapeutic options are limited. Only five targeted agents are approved for treatment—trastuzumab (Roche’s Herceptin,…
Bladder cancer is the eighth most commonly diagnosed cancer in China. The bladder cancer therapy market is set to enter a competitive and dynamic period of rapid growth, fueled by one of the most…
Of the four subtypes of non-Hodgkin’s lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL) is the most common in China. Rituximab (Roche’s MabThera, biosimilars) continues to dominate China’…
Of the four subtypes of non-Hodgkin’s lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL) is the most common in China. Rituximab (Roche’s MabThera, biosimilars) continues to dominate China’…
Type 2 diabetes (T2D) remains one of the biggest health challenges in China, where the prevalence of disease is globally the highest. Several traditional drug classes such as biguanides and alpha-…
Multiple sclerosis (MS), a chronic immune-mediated disease of the nervous system, is classified as a rare disease in China because of its low prevalence there. Traditionally, patients suffering…
Because of the dearth of targeted treatments in China, patients with relapsed/refractory (R/R) NHL, multiple myeloma, or ALL continue to be prescribed salvage chemotherapy in later lines of…
Non-small-cell lung cancer (NSCLC)—the leading cause of cancer-related deaths in China—has a highly dynamic drug development pipeline, including several targeted and biomarker-driven therapies…
Rheumatoid arthritis (RA) is a chronic and progressive autoimmune disease that primarily affects the joints. China has the highest number of RA patients in the world, and disease management is…